MA32590B1 - Derives de dioxa-bicyclo [3.2.1] octane-2,3,4-triol - Google Patents

Derives de dioxa-bicyclo [3.2.1] octane-2,3,4-triol

Info

Publication number
MA32590B1
MA32590B1 MA33651A MA33651A MA32590B1 MA 32590 B1 MA32590 B1 MA 32590B1 MA 33651 A MA33651 A MA 33651A MA 33651 A MA33651 A MA 33651A MA 32590 B1 MA32590 B1 MA 32590B1
Authority
MA
Morocco
Prior art keywords
dioxa
bicyclo
octane
triol derivatives
compounds
Prior art date
Application number
MA33651A
Other languages
Arabic (ar)
English (en)
Inventor
Vincent Mascitti
Benjamin Micah Collman
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41208284&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32590(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of MA32590B1 publication Critical patent/MA32590B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
    • C07H9/02—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing only oxygen as ring hetero atoms
    • C07H9/04—Cyclic acetals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention concerne des composés de formule (i) et leurs utilisations pour le traitement de maladies, d'affections et/ou de troubles médiés par des inhibiteurs des transporteurs sodium-glucose (en particulier, des inhibiteurs de sglt2). L'invention concerne des composés qui sont utiles pour la prévention et le traitement de l'obésité et de ses co-morbidités associées, en particulier un diabète de type ii (type 2).
MA33651A 2008-08-28 2011-02-28 Derives de dioxa-bicyclo [3.2.1] octane-2,3,4-triol MA32590B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9247008P 2008-08-28 2008-08-28
US22721209P 2009-07-21 2009-07-21
PCT/IB2009/053626 WO2010023594A1 (fr) 2008-08-28 2009-08-17 Dérivés de dioxa-bicyclo[3.2.1.]octane-2,3,4-triol

Publications (1)

Publication Number Publication Date
MA32590B1 true MA32590B1 (fr) 2011-08-01

Family

ID=41208284

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33651A MA32590B1 (fr) 2008-08-28 2011-02-28 Derives de dioxa-bicyclo [3.2.1] octane-2,3,4-triol

Country Status (46)

Country Link
US (1) US8080580B2 (fr)
EP (1) EP2334687B9 (fr)
JP (1) JP4825322B1 (fr)
KR (2) KR101446454B1 (fr)
CN (2) CN103497199B (fr)
AP (1) AP2728A (fr)
AR (1) AR073138A1 (fr)
AT (1) ATE540040T1 (fr)
AU (1) AU2009286380B2 (fr)
BR (1) BRPI0918841B8 (fr)
CA (1) CA2733795C (fr)
CL (1) CL2011000394A1 (fr)
CO (1) CO6341636A2 (fr)
CR (1) CR20110077A (fr)
CY (2) CY1112497T1 (fr)
DK (1) DK2334687T5 (fr)
DO (1) DOP2011000058A (fr)
EA (1) EA018492B1 (fr)
EC (1) ECSP11010854A (fr)
ES (1) ES2380408T3 (fr)
FR (1) FR18C1036I2 (fr)
GE (1) GEP20135803B (fr)
HN (1) HN2009001652A (fr)
HR (1) HRP20120104T1 (fr)
HU (1) HUS1800031I1 (fr)
IL (2) IL211226A (fr)
LT (1) LTC2334687I2 (fr)
MA (1) MA32590B1 (fr)
ME (1) ME01285A (fr)
MX (1) MX2011002166A (fr)
MY (1) MY155418A (fr)
NI (1) NI201100043A (fr)
NL (1) NL300943I2 (fr)
NO (1) NO2018019I2 (fr)
NZ (1) NZ591027A (fr)
PA (1) PA8840801A1 (fr)
PE (1) PE20110288A1 (fr)
PL (1) PL2334687T3 (fr)
PT (1) PT2334687E (fr)
RS (1) RS52236B (fr)
SI (1) SI2334687T1 (fr)
SV (1) SV2011003842A (fr)
TW (1) TWI387598B (fr)
UY (1) UY32073A (fr)
WO (1) WO2010023594A1 (fr)
ZA (1) ZA201101341B (fr)

Families Citing this family (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009270936B2 (en) 2008-07-15 2014-12-18 Theracos, Inc. Deuterated benzylbenzene derivatives and methods of use
RS53827B1 (sr) 2009-11-02 2015-06-30 Pfizer Inc. Derivati dioksa-biciklo[3.2.1]oktan-2,3,4-triola
DK2547679T3 (en) 2010-03-19 2016-01-11 Pfizer 2,3 dihydro-1H-inden-1-yl-2,7-diazaspiro [3.6] nonane derivatives and their use as antagonists or inverse agonists of ghrelin receptor
CN102372722A (zh) * 2010-08-10 2012-03-14 江苏恒瑞医药股份有限公司 C-芳基葡萄糖苷衍生物、其制备方法及其在医药上的应用
WO2012041898A1 (fr) 2010-09-29 2012-04-05 Celon Pharma Sp. Z O.O. Combinaison de l'inhibiteur de sglt2 et d'un composé de sucre pour le traitement du diabète
ES2546465T3 (es) 2010-10-29 2015-09-23 Pfizer Inc Inhibidores de N1/N2-lactama acetil-CoA carboxilasa
WO2012109996A1 (fr) * 2011-02-18 2012-08-23 上海璎黎科技有限公司 Composé aryl glycoside, son procédé de préparation et d'utilisation
EP2680874A2 (fr) 2011-03-04 2014-01-08 Pfizer Inc Peptides de type edn3 et utilisations associées
AU2012245996B2 (en) 2011-04-22 2016-09-01 Pfizer Inc. Pyrazolospiroketone derivatives for use as acetyl-CoA carboxylase inhibitors
BR112013031032A2 (pt) 2011-06-03 2016-11-29 Boehringer Ingelheim Int inibidores de sglt-2 para o tratamento de distúrbios metabólicos em pacientes tratados com agentes neurolépticos
EP2717689A4 (fr) * 2011-06-13 2014-11-05 Panacea Biotec Ltd Nouveaux inhibiteurs sglt
TWI510491B (zh) * 2011-06-30 2015-12-01 Shanghai Hengrui Pharm Co Ltd Ｃ－芳基葡萄糖苷衍生物、其製備方法及其在醫藥上的應用
JP2014520879A (ja) 2011-07-15 2014-08-25 ファイザー・インク Ｇｐｒ１１９調節因子
US8927577B2 (en) 2011-07-22 2015-01-06 Pfizer Inc. Quinolinyl glucagon receptor modulators
JP6043355B2 (ja) 2011-08-31 2016-12-14 ファイザー・インク ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
US9018249B2 (en) 2011-09-13 2015-04-28 Panacea Biotec Limited SGLT inhibitors
WO2013068439A1 (fr) 2011-11-09 2013-05-16 Intervet International B.V. Composés 4-amino-5-oxo-7,8-dihydropyrimido[5, 4 -f] [1, 4] oxazépine comme inhibiteurs de dgat1
CN103917529B (zh) 2011-11-11 2016-08-17 辉瑞大药厂 2-硫代嘧啶酮类
EA201400990A1 (ru) 2012-04-06 2015-01-30 Пфайзер Инк. Ингибиторы диацилглицеринацилтрансферазы 2
WO2013152476A1 (fr) 2012-04-10 2013-10-17 Theracos, Inc. Procédé de préparation d'inhibiteurs de sglt2 benzylbenzène
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
WO2013164730A1 (fr) 2012-05-04 2013-11-07 Pfizer Inc. Composés d'hexahydropyrano[3,4-d][1,3]thiazin-2-amine substitués par des hétérocycliques à titre d'inhibiteurs d'app, bace1 et bace2
CN103570657A (zh) * 2012-07-19 2014-02-12 天津药物研究院 一类含偕二甲基的苯基c-葡萄糖苷衍生物、其制备方法和用途
US9145434B2 (en) 2012-07-26 2015-09-29 Boehringer Ingelheim International Gmbh Crystalline complex of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(ss-d-glucopyranos-1-yl)-benzene, methods for its preparation and the use thereof for preparing medicaments
EP2897964A1 (fr) 2012-09-20 2015-07-29 Pfizer Inc. Composés de hexahydropyrano [3,4-d][1,3]thiazin-2-amine substitués par alkyle
CN103772449B (zh) * 2012-10-26 2017-12-26 上海阳帆医药科技有限公司 C‑芳基葡萄糖苷衍生物及其制备方法与用途
CN103848806B (zh) * 2012-12-05 2016-04-06 广东东阳光药业有限公司 吡喃葡萄糖基衍生物、其制备方法及其在医药上的应用
EP2931731A1 (fr) 2012-12-11 2015-10-21 Pfizer Inc. Composés d'hexahydropyrano [3,4-d][1,3]thiazin-2-amine en tant qu'inhibiteurs de bace1
EP2933250B1 (fr) * 2012-12-17 2017-08-09 Tianjin Institute Of Pharmaceutical Research Dérivé de phényl-c-glucoside contenant une structure de désoxyglucose, procédé de préparation et utilisation de celui-ci
US9403846B2 (en) 2012-12-19 2016-08-02 Pfizer Inc. Carbocyclic- and heterocyclic-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
EP2956458B1 (fr) 2013-02-13 2017-08-09 Pfizer Inc Composés hexahydropyrano[3,4-d][1,3]thiazin-2-amine substitués par un hétéroaryle
US9233981B1 (en) 2013-02-15 2016-01-12 Pfizer Inc. Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
CN104045513A (zh) * 2013-03-14 2014-09-17 爱康药业有限公司 4-取代-1-氯-2-(4-氟苄基)苯及其制备方法和作为中间体在制备抗ii型糖尿病药物中的应用
EP3466431B1 (fr) * 2013-03-14 2023-11-15 MSD International GmbH Formes crystallins et modes preparatoires pour la manufacture des inhibiteurs de sglt2
PT2981269T (pt) 2013-04-04 2023-10-10 Boehringer Ingelheim Vetmedica Gmbh Tratamento de distúrbios metabólicos em animais equinos
CN104619713B (zh) * 2013-05-24 2017-06-16 四川海思科制药有限公司 氧杂双环衍生物、制备方法及其应用
WO2015027963A1 (fr) * 2013-09-02 2015-03-05 四川海思科制药有限公司 Dérivé à noyau aromatique, composition pharmaceutique et utilisation associée
ES2605886T3 (es) * 2013-09-27 2017-03-16 Sunshine Lake Pharma Co., Ltd. Derivados de glucopiranosilo y sus usos en medicina
CA2926568C (fr) 2013-10-09 2017-09-05 Pfizer Inc. Antagonistes de recepteur ep3 de prostaglandine
CN105611920B (zh) 2013-10-12 2021-07-16 泰拉科斯萨普有限责任公司 羟基-二苯甲烷衍生物的制备
ES2969764T3 (es) 2013-12-17 2024-05-22 Boehringer Ingelheim Vetmedica Gmbh Un inhibidor de SGLT-2 para usar en el tratamiento de un trastorno metabólico en animales felinos
CN115671290A (zh) 2014-01-23 2023-02-03 勃林格殷格翰动物保健有限公司 犬科动物中代谢紊乱的治疗
LT3119757T (lt) 2014-03-17 2018-07-10 Pfizer Inc. Diacilglicerolio aciltransferazės 2 inhibitoriai, skirti panaudoti metabolinių ir susijusių ligų gydyme
WO2015150299A2 (fr) 2014-04-01 2015-10-08 Boehringer Ingelheim Vetmedica Gmbh Traitement de troubles métaboliques chez les équidés
DK3126330T3 (en) 2014-04-04 2019-04-23 Pfizer BICYCLE-FUSED HETEROARYL OR ARYL COMPOUNDS AND USE THEREOF AS IRAC4 INHIBITORS
CN106459088A (zh) 2014-04-10 2017-02-22 辉瑞公司 2‑氨基‑6‑甲基‑4，4a，5，6‑四氢吡喃并[3，4‑d][1，3]噻嗪‑8a(8H)‑基‑1，3‑噻唑‑4‑基酰胺
PL3145934T3 (pl) 2014-05-19 2021-08-16 Pfizer Inc. Podstawione związki 6,8-dioksabicyklo[3.2.1]oktano-2,3-diolu jako środki kierujące do ASGPR
CN104017031A (zh) * 2014-06-21 2014-09-03 李友香 降血糖药物和组合物
CN104031098A (zh) * 2014-06-21 2014-09-10 李友香 降糖药物
WO2016046150A1 (fr) 2014-09-25 2016-03-31 Boehringer Ingelheim Vetmedica Gmbh Polythérapie avec des inhibiteurs de sglt2 et des agonistes de la dopamine utilisée pour la prévention des troubles métaboliques chez des équidés
CN105461762B (zh) * 2014-09-27 2018-12-04 广东东阳光药业有限公司 吡喃葡萄糖基衍生物及其在医药上的应用
HUE052588T2 (hu) * 2014-09-30 2021-05-28 Jiangsu Hengrui Medicine Co Az L-prolin/nátrium-glukóz kotranszporter 2 gátló kristály komplexének kristálya
US10285973B2 (en) * 2014-11-10 2019-05-14 Merck Sharp & Dohme Corp. SGLT-2 inhibitors for treating metabolic disorders in patients with renal impairment or chronic kidney disease
WO2016092413A1 (fr) 2014-12-10 2016-06-16 Pfizer Inc. Composés indoliques et indazoliques qui activent l'ampk
EP3237401B1 (fr) 2014-12-22 2019-03-06 Pfizer Inc Antagonistes de récepteur ep3 de prostaglandine
AU2016257179A1 (en) 2015-05-05 2017-11-02 Pfizer Inc. 2-thiopyrimidinones
WO2016189463A1 (fr) * 2015-05-25 2016-12-01 Sun Pharmaceutical Industries Limited Co-cristaux d'ertuglifozine et procédé pour les préparer
US10308615B2 (en) 2015-05-29 2019-06-04 Pfizer Inc. Heterocyclic compounds as inhibitors of Vanin-1 enzyme
CN107787322B (zh) 2015-06-17 2023-07-07 辉瑞大药厂 三环化合物以及它们作为磷酸二酯酶抑制剂的用途
WO2016203335A1 (fr) 2015-06-18 2016-12-22 Pfizer Inc. Nouvelles pyrido [2,3-b] pyrazinones utilisées en tant qu'inhibiteurs de bromodomaines de la famille bet
WO2017025849A1 (fr) 2015-08-13 2017-02-16 Pfizer Inc. Composés aryle ou hétéroaryle condensés bicycliques
KR102659761B1 (ko) 2015-08-27 2024-04-24 베링거잉겔하임베트메디카게엠베하 Sglt-2 억제제를 포함하는 액상 약제학적 조성물
HUE053705T2 (hu) 2015-08-27 2021-07-28 Pfizer Biciklusos kondenzált heteroaril- vagy aril- vegyületek IRAK4 modulátorokként
WO2017037567A1 (fr) 2015-09-03 2017-03-09 Pfizer Inc. Régulateurs de la frataxine
JP2018534251A (ja) 2015-09-24 2018-11-22 ファイザー・インク Ｂａｃｅ阻害剤として有用なｎ−［２−（３−アミノ−２，５−ジメチル−１，１−ジオキシド−５，６−ジヒドロ−２ｈ−１，２，４−チアジアジン−５−イル）−１，３−チアゾール−４−イル］アミド
WO2017051303A1 (fr) 2015-09-24 2017-03-30 Pfizer Inc. Dérivés de tétrahydropyrano[3,4-d] [1,3]oxazine et leur utilisation en tant qu'inhibiteurs de bace
JP2018531923A (ja) 2015-09-24 2018-11-01 ファイザー・インク Ｎ−［２−（２−アミノ−６，６−二置換−４，４ａ，５，６−テトラヒドロピラノ［３，４−ｄ］［１，３］チアジン−８ａ（８Ｈ）−イル）−１，３−チアゾール−４−イル］アミド
SI3397631T1 (sl) 2015-12-29 2022-01-31 Pfizer Inc. Substituirani 3-azabiciklo(3.1.0)heksani kot zaviralci ketoheksokinaze
DK3404033T3 (da) 2016-01-04 2020-11-02 Jeil Pharmaceutical Co Ltd C-glukosidderivat med kondenseret phenylring eller farmaceutisk acceptabelt salt deraf, fremgangsmåde til fremstilling deraf og farmaceutisk sammensætning indeholdende dette
CN105646603A (zh) * 2016-03-01 2016-06-08 孙霖 埃格列净晶型a及制备方法
CN105646604A (zh) * 2016-03-01 2016-06-08 孙霖 埃格列净晶型b及制备方法
EP3426256A4 (fr) * 2016-03-11 2019-11-06 Merck Sharp & Dohme Corp. Procédé de traitement ou de réduction du risque d'événements cardiovasculaires et de maladies associées au moyen d'inhibiteur de sglt-2
WO2018011681A1 (fr) 2016-07-14 2018-01-18 Pfizer Inc. Nouveaux pyrimidine carboxamides utilisées comme inhibiteurs de l'enzyme vanin-1
WO2018011721A1 (fr) * 2016-07-15 2018-01-18 Granules India Limited Nouvelles formes polymorphes de ((1s,2s,3s,4r,5s))-2,3,4-(tris-benzyloxy)-5-(4-chloro-3-(4-éthoxy-benzyl)phényl)-6,8-dioxa-bicyclo[3.2.1]oct-1-yl-méthanol
AR109179A1 (es) 2016-08-19 2018-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
US20210212968A1 (en) 2016-10-19 2021-07-15 Boehringer Ingelheim International Gmbh Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof
CN107382952B (zh) * 2017-07-13 2020-02-28 杭州科巢生物科技有限公司 埃格列净的制备方法及其中间体
CN111405899B (zh) 2017-11-30 2025-05-16 爱杜西亚药品有限公司 用于治疗内皮素相关疾病的4-嘧啶磺酰胺衍生物与sglt-2抑制剂的组合
CN107898764A (zh) * 2017-12-12 2018-04-13 威海贯标信息科技有限公司 一种埃格列净组合物
WO2019133445A1 (fr) 2017-12-28 2019-07-04 Inception Ibd, Inc. Aminothiazoles utilisés en tant qu'inhibiteurs de vanin-1
CN107857768A (zh) * 2018-01-04 2018-03-30 威海贯标信息科技有限公司 一种埃格列净新晶型
CN111566112B (zh) * 2018-03-06 2022-02-15 广东东阳光药业有限公司 埃格列净的晶型及其制备方法
CN111989103A (zh) 2018-04-17 2020-11-24 勃林格殷格翰国际有限公司 药物组合物、其治疗方法和用途
WO2019202149A1 (fr) 2018-04-19 2019-10-24 Université Catholique de Louvain Inhibiteurs de sglt2 pour le traitement de la neutropénie
WO2020001812A1 (fr) 2018-06-25 2020-01-02 Pharmathen S.A. Nouveau procédé de préparation d'inhibiteurs de sglt-2
WO2020026273A1 (fr) * 2018-07-31 2020-02-06 Msn Laboratories Private Limited, R&D Center Formes solides de base libre d'ertugliflozine et dispersions à l'état solide comprenant de l'acide ertugliflozin l-pyroglutamique
WO2020039394A1 (fr) 2018-08-24 2020-02-27 Novartis Ag Nouvelles combinaisons de médicaments
US11254660B2 (en) 2018-08-31 2022-02-22 Pfizer Inc. Combinations for treatment of NASH/NAFLD and related diseases
WO2020102575A1 (fr) 2018-11-16 2020-05-22 Inception Ibd, Inc. Aminothiazoles hétérocycliques et leurs utilisations
WO2020234726A1 (fr) 2019-05-20 2020-11-26 Pfizer Inc. Combinaisons comprenant du benzodioxol en tant qu'agonistes de glp-1r destinées à être utilisées dans le traitement de la nash/nafld et de maladies associées
WO2020261144A1 (fr) 2019-06-28 2020-12-30 Pfizer Inc. Dérivés de 5-(thiophén-2-yl) -1h-tétrazole utilisés en tant qu'inhibiteurs de bckdk utiles pour le traitement de diverses maladies
TW202115086A (zh) 2019-06-28 2021-04-16 美商輝瑞大藥廠 Bckdk抑制劑
EP3997079A4 (fr) * 2019-07-10 2023-03-01 Sunshine Lake Pharma Co., Ltd. Dérivés de glucopyranosyle et leurs utilisations
TWI771766B (zh) 2019-10-04 2022-07-21 美商輝瑞股份有限公司 二醯基甘油醯基轉移酶２ 抑制劑
EP4064854A1 (fr) 2019-11-28 2022-10-05 Boehringer Ingelheim Vetmedica GmbH Utilisation d'inhibiteurs de sglt-2 dans le séchage de mammifères non humains
WO2021121270A1 (fr) * 2019-12-19 2021-06-24 上海研健新药研发有限公司 Procédé de purification d'un inhibiteur des sglt et utilisation associée
HRP20241159T1 (hr) 2020-02-07 2024-12-06 Gasherbrum Bio, Inc. Heterociklički agonisti za glp-1
AU2021222297B2 (en) 2020-02-17 2026-01-22 Boehringer Ingelheim Vetmedica Gmbh Use of SGLT-2 inhibitors for the prevention and/or treatment of cardiac diseases in felines
JP2022058085A (ja) 2020-02-24 2022-04-11 ファイザー・インク ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ
CA3180674A1 (fr) 2020-04-22 2021-10-28 Bayer Aktiengesellschaft Combinaison de finerenone et d'un inhibiteur de sglt2 pour le traitement et/ou la prevention de maladies cardiovasculaires et/ou renales
TW202206429A (zh) 2020-04-29 2022-02-16 美商迦舒布魯姆生物有限公司 雜環ｇｌｐ—１促效劑
JP7288554B1 (ja) 2020-06-09 2023-06-07 ファイザー・インク メラノコルチン４受容体アンタゴニストとしてのスピロ化合物およびそれらの使用
WO2021260498A1 (fr) * 2020-06-22 2021-12-30 Aurobindo Pharma Limited Procédé de purification amélioré pour la préparation de co-cristal d'acide ertugliflozine et d'ertugliflozin l-pyroglutamique
CN114195748B (zh) * 2020-09-17 2023-11-14 上海森辉医药有限公司 一种钠-葡萄糖协同转运蛋白2抑制剂的制备方法
JP2024525981A (ja) 2021-07-28 2024-07-12 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー ヒト以外の哺乳動物における腎疾患の予防及び／又は治療のためのｓｇｌｔ－２阻害剤の使用
US20240269105A1 (en) 2021-07-28 2024-08-15 Boehringer Ingelheim Vetmedica Gmbh Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals
JP2024527434A (ja) 2021-07-28 2024-07-24 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー ネコ科動物を除く非ヒト哺乳動物、特にイヌ科動物における心臓疾患の予防及び／又は治療のためのｓｇｌｔ－２阻害剤の使用
US20250066337A1 (en) 2021-08-26 2025-02-27 Pfizer Inc. Amorphous Form of (S)-2-(5-((3-Ethoxypyridin-2-YL)Oxy)Pyridin-3-YL)-N-(Tetrahydrofuran-3-YL)Pyrimidine-5-Carboxamide
KR20230060921A (ko) 2021-10-28 2023-05-08 유니셀랩 주식회사 에르투글리플로진의 신규 전구체
CA3240990A1 (fr) 2021-12-01 2023-06-08 Pfizer Inc. Derives d'acide 3-phenyl-1-benzothiophene-2-carboxylique utilises en tant qu'inhibiteurs de kinase alpha-ceto-acide a chaine ramifiee pour le traitement du diabete, de maladies re nales, de la shna et de l'insuffisance cardiaque
JP2024544021A (ja) 2021-12-06 2024-11-26 ファイザー・インク メラノコルチン４受容体アンタゴニストおよびそれらの使用
JP2025509281A (ja) 2022-03-09 2025-04-11 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環式ｇｌｐ－１アゴニスト
US20250250269A1 (en) 2022-04-14 2025-08-07 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
AU2023277704A1 (en) 2022-05-25 2024-12-05 Boehringer Ingelheim Vetmedica Gmbh Aqueous pharmaceutical compositions comprising sglt-2 inhibitors
KR20250075705A (ko) 2022-10-07 2025-05-28 화이자 인코포레이티드 Hsd17b13 억제제 및/또는 분해제
AU2023364628A1 (en) 2022-10-18 2025-04-03 Pfizer Inc. Patatin-like phospholipase domain-containing protein 3 (pnpla3) modifiers
WO2024118524A1 (fr) 2022-11-28 2024-06-06 Cerevel Therapeutics, Llc Composés d'azaindole et leur utilisation en tant qu'inhibiteurs de phosphodiestérase
TW202435857A (zh) 2022-12-15 2024-09-16 美商迦舒布魯姆生物有限公司 具有glp-1促效劑活性之化合物之鹽及固體形式
EP4634169A1 (fr) 2022-12-16 2025-10-22 Pfizer Inc. Inhibiteurs et/ou agents de dégradation contenant du 3-fluoro-4-hydroxybenzmide et leurs utilisations
EP4676494A1 (fr) 2023-03-06 2026-01-14 Boehringer Ingelheim Vetmedica GmbH Systèmes d'administration de compositions pharmaceutiques liquides comprenant en particulier un ou plusieurs inhibiteurs de sglt-2
EP4695226A1 (fr) 2023-04-14 2026-02-18 Pfizer Inc. Antagonistes du récepteur du polypeptide insulinotrope dépendant du glucose et leurs utilisations
KR20260019532A (ko) 2023-05-24 2026-02-10 베링거잉겔하임베트메디카게엠베하 하나 이상의 sglt-2 억제제와 텔미사르탄을 포함하는 비인간 포유류의 신장 질환 및/또는 고혈압의 병용 치료 및/또는 예방
US20240390317A1 (en) 2023-05-24 2024-11-28 Boehringer Ingelheim Vetmedica Gmbh Combination treatment and/or prevention of cardiac diseases in non-human mammals comprising one or more sglt-2 inhibitors and pimobendan and/or telmisartan
TW202539633A (zh) 2024-02-01 2025-10-16 美商輝瑞股份有限公司 葡萄糖依賴性促胰島素多肽受體拮抗劑及其用途
US20250326741A1 (en) 2024-04-22 2025-10-23 Pfizer Inc. Glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof
WO2025224069A1 (fr) 2024-04-23 2025-10-30 Bayer Aktiengesellschaft Co-cristaux de finérénone, de pecavaptan et d'inhibiteurs de sglt2
WO2026013531A1 (fr) 2024-07-10 2026-01-15 Pfizer Inc. Composés spiro[2,5]octane
WO2026033382A1 (fr) 2024-08-07 2026-02-12 Pfizer Inc. Modulateurs hétérocycliques de glp-1 r
WO2026042018A1 (fr) 2024-08-21 2026-02-26 Pfizer Inc. Dérivés d'acide 4-4-[(1-{[4-(propan-2-yl) phényl] carbamoyl)-d-prolyl)amino]cyclohexyl}benzoïque en tant qu'antagonistes de gipr pour le traitement du diabète
WO2026078617A1 (fr) 2024-10-11 2026-04-16 Pfizer Inc. Antagonistes du récepteur du polypeptide insulinotrope dépendant du glucose et leurs utilisations
WO2026078672A1 (fr) 2024-10-13 2026-04-16 Pfizer Inc. Antagonistes du récepteur du polypeptide insulinotrope dépendant du glucose et leurs utilisations
WO2026078674A1 (fr) 2024-10-13 2026-04-16 Pfizer Inc. Dérivés hétérocycliques utilisés en tant qu'antagonistes du récepteur polypeptidique insulinotropique dépendant du glucose et leurs utilisations
WO2026078673A1 (fr) 2024-10-13 2026-04-16 Pfizer Inc. Antagonistes du récepteur polypeptidique insulinotropique dépendant du glucose et leurs utilisations
WO2026078670A1 (fr) 2024-10-13 2026-04-16 Pfizer Inc. Dérivés hétérocycliques en tant qu'antagonistes du récepteur du polypeptide insulinotrope dépendant du glucose
WO2026078671A1 (fr) 2024-10-13 2026-04-16 Pfizer Inc. Composés hétérocycliques utilisés en tant qu'antagonistes du récepteur polypeptidique insulinotropique dépendant du glucose
CN120531728B (zh) * 2025-07-28 2025-09-19 华南农业大学 焦谷氨酸在制备抑制脂肪沉积产品中的应用

Family Cites Families (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US560230A (en) * 1896-05-19 powers
US486299A (en) * 1892-11-15 John k
US247705A (en) * 1881-09-27 William a
US838442A (en) * 1906-05-31 1906-12-11 Oscar Mietens Compressed-air railway-train brake.
FR1499439A (fr) * 1966-09-16 1967-10-27 Electrochimie Soc Nouveau polyol et procédé pour sa préparation
JPS5373598A (en) * 1976-12-11 1978-06-30 Teikoku Chem Ind Corp Ltd Saccharide derivatives and process for thir preparation
JPS5911600B2 (ja) * 1981-04-30 1984-03-16 理化学研究所 ３−アジド−１，６−アンヒドロ−３−デオキシ−２，４−ジ−Ｏ−ベンジル−β−Ｄ−グルコピラノ−ス及びその製造法
NZ214774A (en) 1986-01-08 1989-10-27 Nz Scientific & Ind Res Herbicidal and/or plant growth regulatory compositions based on 1,6-anhydro-beta-hexopyranose derivatives and certain of these derivatives
US5041541A (en) 1988-05-05 1991-08-20 The Procter & Gamble Company Functional sugar substituted with reduced calories
CN1020944C (zh) 1990-01-30 1993-05-26 阿图尔-费希尔股份公司费希尔厂 紧固件
CA2079544A1 (fr) 1991-10-04 1993-04-05 Adam Weislaw Mazur Composes permettant de faire baisser le taux de cholesterol
DE4400464A1 (de) * 1994-01-11 1995-07-13 Bayer Ag Endoparasitizide Mittel
PT850948E (pt) 1996-12-26 2002-08-30 Tanabe Seiyaku Co Derivados propiofenona e processo para a preparacao dos mesmos
US6486299B1 (en) 1998-09-28 2002-11-26 Curagen Corporation Genes and proteins predictive and therapeutic for stroke, hypertension, diabetes and obesity
US6069238A (en) 1998-09-30 2000-05-30 Eli Lilly And Company Spirocyclic C-glycosides
KR100591585B1 (ko) 1999-08-31 2006-06-20 깃세이 야쿠힌 고교 가부시키가이샤 글루코피라노실옥시피라졸 유도체, 그것을 함유하는 의약조성물 및 그 제조 중간체
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
WO2001042469A1 (fr) 1999-12-10 2001-06-14 Lexicon Genetics Incorporated Nouvelle proteine transporteuse humaine et polynucleotides codant celle-ci
US6627611B2 (en) 2000-02-02 2003-09-30 Kotobuki Pharmaceutical Co Ltd C-glycosides and preparation of thereof as antidiabetic agents
DE10006887A1 (de) 2000-02-16 2001-09-06 Hermann Koepsell Verbindungen, die die Aktivität oder die Konzentration des Regulatorproteins RS1 verändern
DE10008128A1 (de) 2000-02-22 2001-08-23 Bayer Ag Endoparasitizide Mittel
NZ521369A (en) 2000-03-17 2004-07-30 Kissei Pharmaceutical Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates for the preparation of the derivatives
US6683056B2 (en) 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
US6555519B2 (en) 2000-03-30 2003-04-29 Bristol-Myers Squibb Company O-glucosylated benzamide SGLT2 inhibitors and method
SK287811B6 (sk) 2000-09-29 2011-10-04 Kissei Pharmaceutical Co., Ltd Glukopyranozyloxybenzylbenzénový derivát, farmaceutická kompozícia a ľudský SGLT2-inhibítor tento derivát obsahujúci a použitie tohto derivátu
ES2337127T3 (es) 2000-11-02 2010-04-21 Ajinomoto Co., Inc. Nuevos derivados de pirazol y remedios contra la diabetes que los contienen.
EP1344780A4 (fr) 2000-11-30 2004-01-28 Kissei Pharmaceutical Derives de glucopyranosyloxybenzylbenzene, compositions medicinales contenant ces derives et produits intermediaires obtenus lors de l'elaboration de ces compositions
US20020081678A1 (en) 2000-12-11 2002-06-27 Gennady Merkulov Isolated nucleic acid molecules encoding human transporter proteins, and uses thereof
WO2002053738A1 (fr) 2000-12-28 2002-07-11 Takeda Chemical Industries, Ltd. Nouvelles proteines et adn correspondant
ATE431830T1 (de) 2000-12-28 2009-06-15 Kissei Pharmaceutical Glucopyranosylpyrazolderivate und deren verwendung in arzneimitteln
TWI255817B (en) 2001-02-14 2006-06-01 Kissei Pharmaceutical Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof
US7087579B2 (en) 2001-02-26 2006-08-08 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxypyrazole derivatives and medicinal use thereof
JP4147111B2 (ja) 2001-02-27 2008-09-10 キッセイ薬品工業株式会社 グルコピラノシルオキシピラゾール誘導体およびその医薬用途
US6936590B2 (en) 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
CA2442651A1 (fr) 2001-03-27 2002-10-17 Pe Corporation (Ny) Proteines transporteur humaines isolees, molecules d'acide nucleique codant ces proteines transporteur humaines et utilisations de ces dernieres
WO2002080935A1 (fr) 2001-04-04 2002-10-17 Ortho Mcneil Pharmaceutical, Inc. Polytherapie comprenant des inhibiteurs de reabsorption du glucose et des modulateurs du recepteur x du retinoide
CN100577175C (zh) 2001-04-04 2010-01-06 奥索-麦克尼尔药品公司 包括葡萄糖重吸收抑制剂和ppar调节剂的联合疗法
AU2002338643A1 (en) 2001-04-10 2002-10-28 Millennium Pharmaceuticals, Inc. 68723, sodium/glucose cotransporter family members and uses therefor
AU2002254567B2 (en) 2001-04-11 2007-10-11 Bristol-Myers Squibb Company Amino acid complexes of C-aryl glucosides for treatment of diabetes and method
CA2672001A1 (fr) 2001-04-27 2002-11-07 Ajinomoto Co., Inc. Derives pyrazolyl-o-glycoside n-substitues et medicament contre le diabete en contenant
JP4399251B2 (ja) 2001-05-30 2010-01-13 キッセイ薬品工業株式会社 グルコピラノシルオキシピラゾール誘導体、それを含有する医薬組成物、その医薬用途およびその製造中間体
US7271153B2 (en) 2001-06-20 2007-09-18 Kissei Pharmaceutical Co., Ltd. Nitrogenous heterocyclic derivatives, medicinal compositions containing the same, medicinal uses thereof, and intermediates therefor
JP4115105B2 (ja) 2001-07-02 2008-07-09 協和醗酵工業株式会社 ピラゾール誘導体
US7082091B2 (en) * 2001-07-31 2006-07-25 Ricoh Company, Ltd. Information reproducing method judging a multivalued level of a present cell by referring to judged multivalued levels of a preceding cell and an ensuing cell
MXPA04009229A (es) 2002-03-22 2004-11-26 Kissei Pharmaceutical Cristales derivados de glucopiranosiloxibencil benceno.
US20070059356A1 (en) 2002-05-31 2007-03-15 Almarsson Oern Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
DE10225844A1 (de) 2002-06-04 2003-12-18 Lang Florian sgk und nedd als diagnostische und therapeutische targets
DE10231370B4 (de) 2002-07-11 2006-04-06 Sanofi-Aventis Deutschland Gmbh Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
TWI254635B (en) 2002-08-05 2006-05-11 Yamanouchi Pharma Co Ltd Azulene derivative and salt thereof
RU2356906C2 (ru) 2002-08-08 2009-05-27 Киссеи Фармасьютикал Ко., Лтд. Производные пиразола, лекарственные композиции, содержащие эти производные, их применение в медицине и промежуточные соединения для их получения
DE10237085A1 (de) 2002-08-09 2004-02-19 Bioagency Ag Verwendung von phosphororganischen Verbindungen zur therapeutischen und prophylaktischen Behandlung von Infektionen
RU2322449C2 (ru) 2002-08-09 2008-04-20 Тайсо Фармасьютикал Ко., Лтд. ПРОИЗВОДНЫЕ АРИЛ 5-ТИО-β-D-ГЛЮКОПИРАНОЗИДА И ТЕРАПЕВТИЧЕСКИЕ СРЕДСТВА ПРИ ДИАБЕТЕ, СОДЕРЖАЩИЕ ИХ
JP2004137245A (ja) 2002-08-23 2004-05-13 Kissei Pharmaceut Co Ltd ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
WO2004039405A1 (fr) 2002-10-29 2004-05-13 Takeda Pharmaceutical Company Limited Utilisation de l'homologue de sglt
JP4651934B2 (ja) 2002-12-04 2011-03-16 キッセイ薬品工業株式会社 ベンジルフェノール誘導体、それを含有する医薬組成物およびその医薬用途
US20060035844A1 (en) 2002-12-04 2006-02-16 Fumiaki Ito Preventive or remedy for diseases caused by hyperglycemia
DE10258008B4 (de) 2002-12-12 2006-02-02 Sanofi-Aventis Deutschland Gmbh Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
DE10258007B4 (de) 2002-12-12 2006-02-09 Sanofi-Aventis Deutschland Gmbh Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
JP4679155B2 (ja) 2002-12-25 2011-04-27 キッセイ薬品工業株式会社 含窒素複素環誘導体、それを含有する医薬組成物およびその医薬用途
JP2006516257A (ja) 2003-01-03 2006-06-29 ブリストル−マイヤーズ　スクイブ　カンパニー Ｃ−アリールグルコシドｓｇｌｔ２阻害剤の製造法
CN1771334A (zh) 2003-03-07 2006-05-10 施瑞修德制药公司 用于确定肿瘤对抗肿瘤药剂的治疗的敏感性的方法
ES2363941T3 (es) 2003-03-14 2011-08-19 Astellas Pharma Inc. Derivados de c-glucósido para el tratamiento de diabetes.
JP2004300102A (ja) 2003-03-31 2004-10-28 Kissei Pharmaceut Co Ltd 縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途
EP1609799A4 (fr) 2003-04-01 2008-10-29 Taisho Pharmaceutical Co Ltd Derives heteroaryle 5-thio-beta-d-glucopyranoside et medicaments contre le diabete contenant ces derives
US7439232B2 (en) 2003-04-01 2008-10-21 Taisho Pharmaceutical Co., Ltd. Heteroaryl 5-thio-β-D-glucopyranoside derivatives and therapeutic agents for diabetes containing the same
AU2003902263A0 (en) 2003-05-12 2003-05-29 Fujisawa Pharmaceutical Co., Ltd. Monosaccharide compounds
JPWO2004106352A1 (ja) 2003-05-29 2006-07-20 大正製薬株式会社 アルドヘキソピラノース中間体の製造法
JP2004359630A (ja) 2003-06-06 2004-12-24 Yamanouchi Pharmaceut Co Ltd ジフルオロジフェニルメタン誘導体及びその塩
CA2529878C (fr) 2003-06-20 2012-11-20 Kissei Pharmaceutical Co., Ltd. Derive de pyrazole, composition de medicaments contenant ledit derive et intermediaire de production associe
UA86042C2 (en) 2003-08-01 2009-03-25 Янссен Фармацевтика Н.В. Substituted indazole-o-glucosides
ES2531660T3 (es) 2003-08-01 2015-03-18 Mitsubishi Tanabe Pharma Corporation Compuestos novedosos que tienen actividad inhibidora frente a transportador de glucosa dependiente de sodio
US7375090B2 (en) 2003-08-26 2008-05-20 Boehringer Ingelheim International Gmbh Glucopyranosyloxy-pyrazoles, pharmaceutical compositions containing these compounds, the use thereof and processed for the preparation thereof
US7371732B2 (en) 2003-12-22 2008-05-13 Boehringer Ingelheim International Gmbh Glucopyranosyloxy-substituted aromatic compounds, medicaments containing such compounds, their use and process for their manufacture
JP2005247834A (ja) 2004-02-04 2005-09-15 Taisho Pharmaceut Co Ltd ナトリウム依存性グルコース供輸送体２の活性阻害剤
PL381247A1 (pl) 2004-03-04 2007-05-14 Kissei Pharmaceutical Co., Ltd. Skondensowana pochodna heterocykliczna, zawierająca ją kompozycja lecznicza, oraz jej zastosowanie lecznicze
BRPI0508259A (pt) 2004-03-04 2007-07-31 Kissei Pharmaceutical derivado heterocìclico fundido, composição medicinal contendo o mesmo, e uso medicinal do mesmo
CN1950389B (zh) 2004-03-04 2011-01-19 橘生药品工业株式会社 含氮稠环衍生物，含该衍生物的药物组合物，和其作为药物的用途
CN103030617A (zh) 2004-03-16 2013-04-10 贝林格尔.英格海姆国际有限公司 吡喃葡萄糖基取代的苯基衍生物、含该化合物的药物、其用途及其制造方法
DE102004012676A1 (de) * 2004-03-16 2005-10-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Glucopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
JPWO2005095373A1 (ja) 2004-03-31 2008-02-21 キッセイ薬品工業株式会社 ナフタレン誘導体、それを含有する医薬組成物およびその医薬用途
WO2005095372A1 (fr) 2004-03-31 2005-10-13 Kissei Pharmaceutical Co., Ltd. Derive de naphtalene, composition médicinale contenant ledit dérivé et utilisation médicinale de celui-ci
EP1731524A4 (fr) 2004-03-31 2009-05-20 Kissei Pharmaceutical Derive phenole, composition medicinale contenant ce derive, et son usage medicinal
DE102004028241B4 (de) 2004-06-11 2007-09-13 Sanofi-Aventis Deutschland Gmbh Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel
US7393836B2 (en) 2004-07-06 2008-07-01 Boehringer Ingelheim International Gmbh D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
JPWO2006006496A1 (ja) 2004-07-08 2008-04-24 アステラス製薬株式会社 アズレン誘導体の製造方法及びその合成中間体
DE102004034690A1 (de) 2004-07-17 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Methyliden-D-xylopyranosyl-und Oxo-D-xylopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
MX2007000811A (es) 2004-07-21 2007-04-02 Kissei Pharmaceutical Inhibidor de avance de enfermedad atribuida a acumulacion anormal de grasa en el higado.
TW200606129A (en) 2004-07-26 2006-02-16 Chugai Pharmaceutical Co Ltd Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
WO2006010557A1 (fr) 2004-07-27 2006-02-02 Boehringer Ingelheim International Gmbh Cyclenes substitues par d-glucopyranosyle-phenyle, medicaments contenant lesdits composes, leur utilisation et procede de production correspondant
WO2006018150A1 (fr) 2004-08-11 2006-02-23 Boehringer Ingelheim International Gmbh Cycles a substitution d-xylopyranosyl-phenyle, medicaments contenant ces composes, leur utilisation, et leur procede de production
AR051446A1 (es) 2004-09-23 2007-01-17 Bristol Myers Squibb Co Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
JP2006117651A (ja) 2004-09-27 2006-05-11 Taisho Pharmaceut Co Ltd Ｓｇｌｔ２の活性阻害剤
WO2006035796A1 (fr) 2004-09-29 2006-04-06 Kissei Pharmaceutical Co., Ltd. COMPOSÉ HÉTÉROCYCLIQUE AZOTÉ 1-(β-D-GLYCOPYRANOSYL)-3-SUBSTITUÉ, PRÉPARATION THÉRAPEUTIQUE CONTENANT LEDIT COMPOSÉ, ET EMPLOI MÉDICAL DUDIT COMPOSÉ
DE102004048388A1 (de) 2004-10-01 2006-04-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US7750145B2 (en) 2004-11-18 2010-07-06 Kissei Pharmaceutical Co., Ltd. 1-substituted-3-β-D-glucopyranosylated nitrogenous hetero-cyclic compounds and medicines containing the same
JP2008007405A (ja) 2004-12-07 2008-01-17 Takeda Chem Ind Ltd カルボキサミド誘導体
DE602005009745D1 (de) 2004-12-16 2008-10-23 Boehringer Ingelheim Pharma Glucopyranosyl-substituierte benzen-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür
TW200637839A (en) 2005-01-07 2006-11-01 Taisho Pharmaceutical Co Ltd 1-thio-d-glucitol derivatives
TW200637869A (en) * 2005-01-28 2006-11-01 Chugai Pharmaceutical Co Ltd The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
AR053329A1 (es) 2005-01-31 2007-05-02 Tanabe Seiyaku Co Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt)
ES2358342T3 (es) 2005-02-15 2011-05-09 Kissei Pharmaceutical Co., Ltd. Compuesto 1-sustituido-7-(beta-d-glicopiranosiloxi)(aza)indol y composición farmacéutica comprendiendo el mismo.
JP5264183B2 (ja) 2005-02-23 2013-08-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グルコピラノシル置換（（ヘテロ）アリールエチニル−ベンジル）−ベンゼン誘導体及びナトリウム依存性グルコース共輸送体２（ｓｇｌｔ２）インヒビターとしてのそれらの使用
ATE453656T1 (de) 2005-04-15 2010-01-15 Boehringer Ingelheim Int Glucopyranosyl-substituierte (heteroaryloxy- benzyl)-benzen-derivate als sglt-inhibitoren
CA2604333A1 (fr) 2005-04-15 2006-10-19 Cenix Bioscience Gmbh Genes marqueurs humains et agents de diagnostic, de traitement et de prophylaxie des troubles cardio-vasculaires et de l'atherosclerose
JPWO2006115137A1 (ja) 2005-04-22 2008-12-18 キッセイ薬品工業株式会社 ２−アミノベンズイミダゾール誘導体及びその医薬用途
WO2006119038A1 (fr) 2005-04-29 2006-11-09 Naturegen, Inc. Compositions et procedes pour controler l'assimilation de glucose
US7723309B2 (en) 2005-05-03 2010-05-25 Boehringer Ingelheim International Gmbh Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
UA91546C2 (uk) 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
WO2007000445A1 (fr) 2005-06-29 2007-01-04 Boehringer Ingelheim International Gmbh Derives de benzyle-benzene a substitution glucopyranosyle, medicaments contenant de tels composes, utilisation et production de ces derniers
TW200726755A (en) 2005-07-07 2007-07-16 Astellas Pharma Inc A crystalline choline salt of an azulene derivative
AR054871A1 (es) 2005-07-27 2007-07-25 Boehringer Ingelheim Int Derivados de (hetero)cicloalquiletinil-bencil)-benceno sustituidos con glucopiranosilo, medicamentos que contienen dichos compuestos, sus uso y proceso para su fabricacion
US20070036874A1 (en) 2005-08-05 2007-02-15 Litao Zhong Compositions and methods for controlling glucose and lipid uptake from foods
WO2007025943A2 (fr) 2005-08-30 2007-03-08 Boehringer Ingelheim International Gmbh Derives benzyl-benzene substitues par glucopyranosyle, medicaments contenant ces composes, leur utilisation et leur procede de preparation
AU2006289093A1 (en) 2005-09-08 2007-03-15 Boehringer Ingelheim International Gmbh Crystalline forms of 1-chloro-4-(beta-D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene, methods for its preparation and the use thereof for preparing medicaments
US20070099237A1 (en) 2005-10-31 2007-05-03 The Regents Of The University Of Michigan Reaction co-crystallization of molecular complexes or co-crystals
TWI370818B (en) 2006-04-05 2012-08-21 Astellas Pharma Inc Cocrystal of c-glycoside derivative and l-proline
JP2009167104A (ja) 2006-05-02 2009-07-30 Taisho Pharmaceutical Co Ltd フェニル５−チオグリコシド化合物
JP2009167103A (ja) 2006-05-02 2009-07-30 Taisho Pharmaceutical Co Ltd ピラゾリル５−チオグリコシド化合物
PE20080697A1 (es) 2006-05-03 2008-08-05 Boehringer Ingelheim Int Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
US7803778B2 (en) 2006-05-23 2010-09-28 Theracos, Inc. Glucose transport inhibitors and methods of use
DE102006028862A1 (de) 2006-06-23 2007-12-27 Merck Patent Gmbh 3-Amino-imidazo[1,2-a]pyridinderivate
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
US8115017B2 (en) 2006-06-29 2012-02-14 Taisho Pharmaceutical Co., Ltd C-phenyl 1-thioglucitol compound
TWI418556B (zh) 2006-07-27 2013-12-11 Mitsubishi Tanabe Pharma Corp 吲哚衍生物
JP2008050353A (ja) 2006-07-27 2008-03-06 Mitsubishi Tanabe Pharma Corp 医薬組成物
TWI403516B (zh) * 2006-07-27 2013-08-01 Chugai Pharmaceutical Co Ltd To replace spirocyclic alcohol derivatives, and its use as a therapeutic agent for diabetes
TWI432446B (zh) 2006-07-27 2014-04-01 Chugai Pharmaceutical Co Ltd 稠環螺酮縮醇衍生物、及其做為糖尿病治療藥之使用
US20080027014A1 (en) 2006-07-28 2008-01-31 Tanabe Seiyaku Co., Ltd. Novel SGLT inhibitors
TW200817424A (en) 2006-08-04 2008-04-16 Daiichi Sankyo Co Ltd Benzylphenyl glucopyranoside derivatives
CN101121148B (zh) 2006-08-08 2010-05-12 中国科学院大连化学物理研究所 一种含分子筛的流化反应催化剂直接成型方法
WO2008021200A1 (fr) * 2006-08-09 2008-02-21 Dow Global Technologies, Inc. Compositions de polymère expansible à segments multiples se dilatant dans une direction contrôlable
WO2008020011A1 (fr) 2006-08-15 2008-02-21 Boehringer Ingelheim International Gmbh Dérivés de cyclopropyl-benzène à substitution glucopyranosyle, compositions pharmaceutiques contenant de tels composés, leur utilisation en tant qu'inhibiteurs de sglt et leur procédé de fabrication
WO2008034859A1 (fr) 2006-09-21 2008-03-27 Boehringer Ingelheim International Gmbh Dérivés du difluorobenzyl-benzène substitués par glucopyranosyle, médicament contenant ces composés, leur utilisation et procédé pour leur fabrication
AU2007307544A1 (en) 2006-10-13 2008-04-17 Chugai Seiyaku Kabushiki Kaisha Thioglucose spiroketal derivative and use thereof as therapeutic agent for diabetes
DE102006048728A1 (de) 2006-10-16 2008-04-17 Merck Patent Gmbh 3-Amino-imidazo{1,2-a]pyridinderivate
WO2008049923A1 (fr) 2006-10-27 2008-05-02 Boehringer Ingelheim International Gmbh Forme cristalline du 4-(β-d-glucopyranos-1-yl)-1-méthyl-2-[4-((s)-tétrahydrofuran-3-yloxy)benzyl]benzène, procédé pour la préparation de celle-ci et utilisation de celle-ci pour préparer des médicaments
CA2668623A1 (fr) 2006-11-06 2008-05-15 Boehringer Ingelheim International Gmbh Derives de benzyl-benzonitrile substitues par glucopyranosyle, medicaments contenant de tels composes, leur utilisation et procede pour leur fabrication
WO2008115574A1 (fr) 2007-03-21 2008-09-25 Reliant Pharmaceuticals, Inc. Antagoniste cb1 et agent dyslipidémique et/ou régulateur métabolique et procédés de préparation et d'utilisation correspondants
TW200904454A (en) 2007-03-22 2009-02-01 Bristol Myers Squibb Co Methods for treating obesity employing an SGLT2 inhibitor and compositions thereof
PT2183263E (pt) 2007-07-26 2012-01-11 Lexicon Pharmaceuticals Inc Processos e compostos úteis na preparação de inibidores do co-transportador 2 de glucose e sódio
CL2008002425A1 (es) 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composición farmacéutica que comprende un inhibidor de sglt2 y 1-(4-metil-quinazolin-2-il)metil-3metil-7-(-2-butin-1-il)-8-(3-(r)-amino-piperidin-1il)-xantina, un inhibidor de dpp iv y su uso para el tratamiento de la obesidad y de la diabetes tipo 1 y 2 y complicaciones de esta.
NZ583369A (en) 2007-08-23 2011-08-26 Theracos Inc Benzylbenzene derivatives and methods of use
CL2008003653A1 (es) 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
CN101503399B (zh) * 2008-02-04 2012-06-27 白鹭医药技术（上海）有限公司 C-芳基葡萄糖苷sglt2抑制剂

Also Published As

Publication number Publication date
WO2010023594A1 (fr) 2010-03-04
US8080580B2 (en) 2011-12-20
AU2009286380A1 (en) 2010-03-04
EA201100266A1 (ru) 2011-10-31
ECSP11010854A (es) 2011-03-31
MY155418A (en) 2015-10-15
GEP20135803B (en) 2013-04-10
HRP20120104T1 (hr) 2012-02-29
PT2334687E (pt) 2012-04-13
KR20130116078A (ko) 2013-10-22
IL211226A (en) 2015-02-26
FR18C1036I1 (fr) 2018-10-05
EP2334687A1 (fr) 2011-06-22
AU2009286380A8 (en) 2011-03-17
CR20110077A (es) 2011-03-09
TWI387598B (zh) 2013-03-01
NO2018019I2 (no) 2019-02-19
HK1156616A1 (en) 2012-06-15
HN2009001652A (es) 2012-02-13
IL211226A0 (en) 2011-04-28
AR073138A1 (es) 2010-10-13
CY2018024I1 (el) 2019-11-27
BRPI0918841A2 (pt) 2015-12-08
RS52236B (sr) 2012-10-31
CY1112497T1 (el) 2015-12-09
KR101446454B1 (ko) 2014-10-06
CO6341636A2 (es) 2011-11-21
TW201014863A (en) 2010-04-16
JP4825322B1 (ja) 2011-11-30
EA018492B1 (ru) 2013-08-30
EP2334687B1 (fr) 2012-01-04
MX2011002166A (es) 2011-04-07
CL2011000394A1 (es) 2011-06-17
AP2728A (en) 2013-08-31
PE20110288A1 (es) 2011-05-26
LTC2334687I2 (lt) 2019-09-10
AU2009286380B2 (en) 2011-09-15
NL300943I2 (nl) 2018-08-07
AP2011005616A0 (en) 2011-04-30
KR20110045093A (ko) 2011-05-03
IL236804A0 (en) 2015-03-31
NZ591027A (en) 2012-11-30
BRPI0918841B8 (pt) 2021-05-25
CN103497199B (zh) 2015-04-29
EP2334687B9 (fr) 2012-08-08
CA2733795C (fr) 2013-12-31
PA8840801A1 (es) 2010-04-21
ES2380408T9 (es) 2013-02-22
PL2334687T3 (pl) 2012-05-31
HK1193606A1 (en) 2014-09-26
ES2380408T3 (es) 2012-05-11
US20100056618A1 (en) 2010-03-04
NO2018019I1 (no) 2018-06-26
SV2011003842A (es) 2011-03-23
LTPA2018510I1 (lt) 2018-09-25
HUS1800031I1 (hu) 2018-08-28
FR18C1036I2 (fr) 2020-07-24
KR101338540B1 (ko) 2013-12-06
CA2733795A1 (fr) 2010-03-04
CN102149717B (zh) 2014-05-14
BRPI0918841B1 (pt) 2019-10-08
NI201100043A (es) 2011-08-05
DOP2011000058A (es) 2011-03-15
DK2334687T5 (da) 2012-09-10
ZA201101341B (en) 2011-11-30
JP2012500842A (ja) 2012-01-12
DK2334687T3 (da) 2012-04-16
CN103497199A (zh) 2014-01-08
CN102149717A (zh) 2011-08-10
CY2018024I2 (el) 2019-11-27
ME01285A (me) 2013-06-20
IL236804B (en) 2019-06-30
SI2334687T1 (sl) 2012-03-30
ATE540040T1 (de) 2012-01-15
UY32073A (es) 2010-03-26

Similar Documents

Publication Publication Date Title
MA32590B1 (fr) Derives de dioxa-bicyclo [3.2.1] octane-2,3,4-triol
CY1119810T1 (el) Παραγωγα(2s,3r,4r,5s,6r)-2-(4-χλωρο-3-βενζυλφαινυλ)-6-(υδροξυμεθυλ)τετραϋδρο-2h-πυραν-3,4,5-τριολης για χρηση στη θεραπεια του διαβητη
TW200738724A (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
CR9347A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
GEP20135793B (en) Heteroaryls amide derivatives and their use as glucokinase activators
MA32467B1 (fr) Derives de piperidinyle agonistes de gpcr
MY151246A (en) Benzofuranyl derivatives
WO2010111406A3 (fr) Composés et leurs utilisations thérapeutiques
EA200970337A1 (ru) Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
UA107783C2 (en) Isoindoline compounds for use in treating cancer
DK2164331T3 (da) Borholdige små molekyler
EA201290267A1 (ru) Производные диоксабицикло[3.2.1]октан-2,3,4-триола
JO2645B1 (en) Vehicles
ATE542795T1 (de) Benzylpiperazinderivate als motilin- rezeptorantagonisten
EA201490268A1 (ru) Производные циклопропиламида, направленно действующие на гистаминовый н3-рецептор
MA32945B1 (fr) Tétrahydropyrane spiro pyrrolidinone et pipéridinone substituées, leur préparation et leur utilisation thérapeutique
CR10036A (es) Procedimientos para la preparación de derivados de ciclopropilamida
BRPI0811557A2 (pt) composto, composição farmacêutica, método de tratamento ou profilaxia de uma condição inflamatória.
MA32512B1 (fr) Derive de phenanthrenone, compositions et procedes
WO2011046905A3 (fr) Compositions pharmaceutiques
UA103626C2 (en) Dioxabicyclo[3,2,1]octane-2,3,4-triol derivatives
TW200734335A (en) Compounds
UA103416C2 (en) Normal;heading 1;heading 2;heading 3;DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES
CU24003B1 (es) Derivados de dioxa-biciclo(3.2.1)octano-2,3,4-triol